Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at
Wall Str
Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.